Claims (21)
一種治療神經精神疾病的醫藥組成物，包括：一有效量之D-氨基酸氧化酶抑制劑，其係選自由苯甲酸、苯甲酸鹽、苯甲酸酯或其衍生物及山梨酸、山梨酸鹽、山梨酸酯或其衍生物所組成的一群組；以及一有效量之神經藥物藥方，其中該神經藥物藥方是抗精神病藥物；其中該D-氨基酸氧化酶抑制劑的施用量足以增加神經藥物藥方治療神經精神疾病的療效，且該施用量為0.7毫克-2.2克/公斤體重/天。
A pharmaceutical composition for treating neuropsychiatric diseases, comprising: an effective amount of a D-amino acid oxidase inhibitor selected from the group consisting of benzoic acid, benzoate, benzoate or a derivative thereof, and sorbic acid, sorbic acid a group consisting of a salt, a sorbate or a derivative thereof; and an effective amount of a neuropharmaceutical prescription, wherein the neuropharmaceutical prescription is an antipsychotic; wherein the D-amino acid oxidase inhibitor is administered in an amount sufficient to increase the nerve The efficacy of the drug prescription for the treatment of neuropsychiatric diseases, and the application amount is 0.7 mg - 2.2 g / kg body weight / day.
如申請專利範圍第1項之醫藥組成物，其中該D-氨基酸氧化酶抑制劑是苯甲酸、苯甲酸鈉、苯甲酸鉀、苯甲酸鈣或苯甲酸鋰。
The pharmaceutical composition of claim 1, wherein the D-amino acid oxidase inhibitor is benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate or lithium benzoate.
如申請專利範圍第1項之醫藥組成物，其中該D-氨基酸氧化酶抑制劑是山梨酸、山梨酸鈉、山梨酸鉀或山梨酸鈣。
The pharmaceutical composition according to claim 1, wherein the D-amino acid oxidase inhibitor is sorbic acid, sodium sorbate, potassium sorbate or calcium sorbate.
如申請專利範圍第1項之醫藥組成物，其中該抗精神病藥物是：氟哌啶醇、氯丙嗪、氟奮乃靜、奮乃靜、羥哌氯丙嗪、丙氯拉嗪、甲硫達嗪、三氟拉嗪、美索達嗪、丙嗪、三氟丙嗪、左美丙嗪、異丙嗪、硫雜蒽、甲哌硫丙硫蒽、珠氯噻醇、氯氮平、奧氮平、里斯普里酮、喹硫平、齊拉西酮、阿米舒必利、阿塞那平、帕潘立酮、阿立哌唑、多巴胺受體部分促進劑、拉莫三嗪、美金剛、丁苯那嗪、大麻二酚、LY2140023、利培酮、氟哌利多、匹莫齊特、丁醯拉嗪、哢吩那嗪、瑞莫必利、哌乙嗪、舒必利或阿坎酸。
The pharmaceutical composition of claim 1, wherein the antipsychotic drug is: haloperidol, chlorpromazine, fluphenazine, perphenazine, hydroxypiperazine, prochlorperazine, methyl sulfide Dazin, trifluoperazine, mesoridazine, prozazine, triflupromazine, levomelopyrazine, promethazine, thioxanthene, mepazine, chlorhexidine, clozapine, Olanzapine, risperidone, quetiapine, ziprasidone, amisulpride, asenapine, paliperidone, aripiprazole, dopamine receptor partial promoter, lamotrigine, beauty King Kong, tetrabenazine, cannabidiol, LY2140023, risperidone, droperidol, pimozide, butylpyrazine, porphyrin, remiride, piperidazine, sulpiride or acamprosate .
如申請專利範圍第4項之醫藥組成物，其中該抗精神病藥物是
里斯普里酮、氟哌啶醇、氯丙嗪、氯氮平、舒必利、喹硫平、阿米舒必利或阿立哌唑。
For example, the pharmaceutical composition of claim 4, wherein the antipsychotic drug is
Risperidone, haloperidol, chlorpromazine, clozapine, sulpiride, quetiapine, amisulpride or aripiprazole.
一種治療神經精神疾病的醫藥組成物，包括：一治療有效量之D-氨基酸氧化酶抑制劑，其係選自由苯甲酸、苯甲酸鹽、苯甲酸酯或其衍生物及山梨酸、山梨酸鹽、山梨酸酯或其衍生物所組成的一群組；以及一治療有效量之神經藥物藥方，其係選自由抗抑鬱劑、強迫症的治療劑、注意力缺乏過動症的治療劑以及認知障礙及/或神經退化性疾病的治療劑，其中該神經精神疾病為憂鬱症、強迫症、注意力缺乏過動症或認知障礙及/或神經退化性疾病。
A pharmaceutical composition for treating neuropsychiatric diseases, comprising: a therapeutically effective amount of a D-amino acid oxidase inhibitor selected from the group consisting of benzoic acid, benzoate, benzoate or a derivative thereof, and sorbic acid, sorbus a group consisting of an acid salt, a sorbate or a derivative thereof; and a therapeutically effective amount of a neuropharmaceutical prescription selected from the group consisting of an antidepressant, a therapeutic agent for obsessive-compulsive disorder, and a therapeutic agent for attention deficit hyperactivity disorder And a therapeutic agent for a cognitive disorder and/or a neurodegenerative disease, wherein the neuropsychiatric disorder is depression, obsessive-compulsive disorder, attention deficit hyperactivity disorder or cognitive disorder and/or neurodegenerative disease.
如申請專利範圍第6項之醫藥組成物，其中該D-氨基酸氧化酶抑制劑是苯甲酸、苯甲酸鈉、苯甲酸鉀、苯甲酸鈣或苯甲酸鋰。
The pharmaceutical composition of claim 6, wherein the D-amino acid oxidase inhibitor is benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate or lithium benzoate.
如申請專利範圍第6項之醫藥組成物，其中該D-氨基酸氧化酶抑制劑是山梨酸、山梨酸鈉、山梨酸鉀或山梨酸鈣。
The pharmaceutical composition of claim 6, wherein the D-amino acid oxidase inhibitor is sorbic acid, sodium sorbate, potassium sorbate or calcium sorbate.
如申請專利範圍第6項之醫藥組成物，其中該抗抑鬱劑是：一種單胺氧化酶抑制劑、三環抗抑鬱藥、四環抗抑鬱劑、選擇性血清素再吸收抑制劑、去甲腎上腺素及特定的血清素抗抑鬱藥、去甲腎上腺素再吸收抑制劑、去甲腎上腺素-多巴胺再吸收抑制劑或血清素-去甲腎上腺素再吸收抑制劑。
The pharmaceutical composition of claim 6, wherein the antidepressant is: a monoamine oxidase inhibitor, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, norepinephrine and Specific serotonin antidepressants, norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors.
如申請專利範圍第6項之醫藥組成物，其中該抗抑鬱劑是：丙咪嗪、氟西汀、帕羅西汀、依地普崙、西酞普蘭、舍曲林、氟伏沙明、文拉法辛、米那普倫、杜洛西汀、米達紗賓、米安色林、瑞波西汀、阿米替林、去甲替林、普羅替林、地昔
帕明、曲米帕明、安莫散平、安非他酮、安非他酮SR、S-西酞普蘭、氯丙咪嗪、多慮平、異卡波肼、維拉法辛XR、反苯環丙胺、曲唑酮、奈法唑酮、苯乙肼、拉莫三嗪、鋰、托吡酯、加巴噴丁、卡馬西平、奧卡西平、丙戊鹽酸、馬普替林、法羅明、吉哌隆、嗎氯貝胺、異煙肼或異菸鹼異丙醯肼。
For example, the pharmaceutical composition of claim 6 wherein the antidepressant is: imipramine, fluoxetine, paroxetine, escitalopram, citalopram, sertraline, fluvoxamine, and venla Fascin, milnacipran, duloxetine, midazan, mianserin, reboxetine, amitriptyline, nortriptyline, protriptyline, ground
Pamin, trimipramine, anemoxan, bupropion, bupropion SR, S-citalopram, clomipramine, doxepin, isocarbophil, verafaxine XR, Benzalilamide, trazodone, nefazodone, phenelzine, lamotrigine, lithium, topiramate, gabapentin, carbamazepine, oxcarbazepine, proglycolic acid, maprotiline, faromin, Gepirone, moclobemide, isoniazid or isonicotine isopropyl hydrazine.
如申請專利範圍第6項之醫藥組成物，其中該注意力缺乏過動症的治療劑是：安非他命類藥物、莫達非尼、迪塑息、可卡因、檳榔鹼、右哌甲酯、哌醋甲酯、二甲磺酸賴右苯丙胺、安非他命混合鹽、托莫西汀、鹽酸可樂定、鹽酸胍法辛或匹莫林。
For example, the pharmaceutical composition of claim 6 of the patent scope, wherein the therapeutic agent lacking attention deficit hyperactivity disorder is: amphetamine, modafinil, dimethoate, cocaine, arecoline, dexamethasone, vinegar Methyl ester, dextroamphetamine dimethacrylate, amphetamine mixed salt, tomoxetine, clonidine hydrochloride, guanfacine hydrochloride or pimoline.
如申請專利範圍第6項之醫藥組成物，其中該認知障礙及/或神經退化性疾病是：失智症、帕金森氏病、良性健忘、輕度認知功能障礙、老年癡呆症、額葉顳葉癡呆、路易體癡呆症、愛滋病癡呆症、多發梗塞性癡呆、血管性癡呆、脊髓小腦平衡失調或進行性核上型麻痺；且該認知障礙及/或神經退化性疾病的治療劑是：美金剛、安理申、多奈哌齊組、他克林、卡巴拉汀、毒扁豆鹼、菸鹼、檳榔鹼、石杉鹼甲、吉蘭、利魯唑、維生素C、維生素E、類胡蘿蔔素或銀杏。
For example, the pharmaceutical composition of claim 6 wherein the cognitive impairment and/or neurodegenerative diseases are: dementia, Parkinson's disease, benign amnesia, mild cognitive dysfunction, Alzheimer's disease, frontal lobe Leaf dementia, Lewy body dementia, AIDS dementia, multiple infarction dementia, vascular dementia, spinal cord imbalance or progressive supranuclear palsy; and the therapeutic agent for cognitive and/or neurodegenerative diseases is: King Kong, Anritsu, donepezil, tacrine, rivastigmine, physostigmine, nicotine, arecoline, huperzine A, geland, riluzole, vitamin C, vitamin E, carotenoids or ginkgo.
如申請專利範圍第12項之醫藥組成物，其中該認知障礙及/或神經退化性疾病是失智症，且該認知障礙及/或神經退化性疾病的治療劑是安理申。
The pharmaceutical composition of claim 12, wherein the cognitive disorder and/or neurodegenerative disease is dementia, and the therapeutic agent for the cognitive disorder and/or neurodegenerative disease is Arison.
一種D-氨基酸氧化酶抑制劑的用途，其係用來製備治療神經精神疾病的藥物，其中該D-氨基酸氧化酶抑制劑係選自由苯甲酸、苯甲酸鹽、苯甲酸酯或其衍生物及山梨酸、山梨酸鹽、
山梨酸酯或其衍生物所組成的一群組，且其施用量為0.7毫克-2.2克/公斤體重/天。
A use of a D-amino acid oxidase inhibitor for the preparation of a medicament for treating a neuropsychiatric disease, wherein the D-amino acid oxidase inhibitor is selected from the group consisting of benzoic acid, benzoate, benzoate or a derivative thereof And sorbic acid, sorbate,
A group consisting of sorbate or a derivative thereof, and is applied in an amount of from 0.7 mg to 2.2 g/kg body weight per day.
如申請專利範圍第14項之用途，其中該D-氨基酸氧化酶抑制劑是苯甲酸、苯甲酸鈉、苯甲酸鉀、苯甲酸鈣或苯甲酸鋰。
The use of the invention of claim 14, wherein the D-amino acid oxidase inhibitor is benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate or lithium benzoate.
如申請專利範圍第14項之用途，其中該D-氨基酸氧化酶抑制劑是山梨酸、山梨酸鈉、山梨酸鉀或山梨酸鈣。
The use of the invention of claim 14, wherein the D-amino acid oxidase inhibitor is sorbic acid, sodium sorbate, potassium sorbate or calcium sorbate.
如申請專利範圍第14項之用途，其中該神經精神疾病為精神分裂症、認知障礙及/或神經退化性疾病、憂鬱症、注意力缺乏過動症或強迫症。
The use of claim 14, wherein the neuropsychiatric disorder is schizophrenia, cognitive impairment and/or neurodegenerative disease, depression, attention deficit hyperactivity disorder or obsessive-compulsive disorder.
一種D-氨基酸氧化酶抑制劑與一神經藥物藥方合併用來製備治療神經精神疾病藥物的用途，其中：該D-氨基酸氧化酶抑制劑係選自由苯甲酸、苯甲酸鹽、苯甲酸酯或其衍生物及山梨酸、山梨酸鹽、山梨酸酯或其衍生物所組成的一群組，且其施用量為0.7毫克-2.2克/公斤體重/天；該神經藥物藥方係選自由抗精神病藥物、抗抑鬱劑、強迫症的治療劑、注意力缺乏過動症的治療劑以及認知障礙及/或神經退化性疾病的治療劑所組成的一群組。
A D-amino acid oxidase inhibitor is used in combination with a neuropharmaceutical to prepare a medicament for treating a neuropsychiatric disease, wherein the D-amino acid oxidase inhibitor is selected from the group consisting of benzoic acid, benzoate, and benzoate. Or a derivative thereof and a group consisting of sorbic acid, sorbate, sorbate or a derivative thereof, and the application amount thereof is 0.7 mg to 2.2 g / kg body weight / day; the neuropharmaceutical prescription is selected from the group consisting of A group consisting of a psychiatric drug, an antidepressant, a therapeutic agent for obsessive-compulsive disorder, a therapeutic agent for attention deficit hyperactivity disorder, and a therapeutic agent for cognitive disorders and/or neurodegenerative diseases.
如申請專利範圍第18項之用途，其中該D-氨基酸氧化酶抑制劑是苯甲酸、苯甲酸鈉、苯甲酸鉀、苯甲酸鈣或苯甲酸鋰。
The use of claim 18, wherein the D-amino acid oxidase inhibitor is benzoic acid, sodium benzoate, potassium benzoate, calcium benzoate or lithium benzoate.
如申請專利範圍第18項之用途，其中該D-氨基酸氧化酶抑制劑是山梨酸、山梨酸鈉、山梨酸鉀或山梨酸鈣。
The use of claim 18, wherein the D-amino acid oxidase inhibitor is sorbic acid, sodium sorbate, potassium sorbate or calcium sorbate.
如申請專利範圍第18項之用途，其中該神經精神疾病為精神分裂症、憂鬱症、強迫症、注意力缺乏過動症或認知障礙及/或神經退化性疾病。
The use of claim 18, wherein the neuropsychiatric disorder is schizophrenia, depression, obsessive-compulsive disorder, attention deficit hyperactivity disorder or cognitive impairment and/or neurodegenerative disease.